BrainXell, Inc. Strengthens Executive Leadership with Paul Marcus and Dr. Su-Chun Zhang

MADISON, Wis., July 17, 2025 /PRNewswire/ -- BrainXell, a leading producer of iPSC-derived human neurons and glia, is proud to announce the continued growth of its executive leadership team with the appointment of Paul Marcus as President, Chief Operating Officer, Chief Financial Officer and Board of Directors. 

The company also continues to benefit from the scientific leadership of its founder, Dr. Su-Chun Zhang, an internationally recognized expert in stem cell neuroscience whose groundbreaking work in human iPSC differentiation and CNS development underpins BrainXell's core technology platform. He now serves as Advising Chief Scientific Officer. 

"We are incredibly fortunate to have Paul and Su-Chun guiding BrainXell at this pivotal time," said Katherine Vega Stultz, CEO of BrainXell. "Their leadership reflects the heart of BrainXell's work, combining scientific breakthroughs with operational strength to accelerate progress in both our research tools and therapeutics businesses."

Mr. Marcus has decades of institutional investment experience in life sciences and broader market sectors. Mr. Marcus began his career as an executive with Bank of America and then with Morgan Stanley, followed by serving as CEO of Winchester Capital and its successor companies. Concurrently, Mr. Marcus has served in executive/c-suite positions with several market leaders in China, including: VIPKID, AINemo, Digital Domain, and 01.ai. In addition, Mr. Marcus is an Emeritus Member of the St. Jude Children's Research Hospital Board of Directors and Governors and a Governing Trustee of the Board of Trustees of the Dana-Farber Cancer Institute.

Dr. Su-Chun Zhang's research laid the scientific foundation for BrainXell's proprietary iPSC technology, which enables the generation of high-purity, functionally mature CNS cells for research and drug discovery. As a faculty member at the Sanford Burnham Prebys Medical Discovery Institute, he continues to advance the field of regenerative neuroscience. Since its founding in 2015, BrainXell has grown into an industry leader, supporting biotech and pharma partners worldwide while advancing a therapeutic pipeline aimed at addressing complex neurological diseases.

About BrainXell
BrainXell was established to translate cutting-edge stem cell science into meaningful tools and therapies for neuroscience. Using its proprietary technology to guide human iPSCs into highly enriched CNS cell types, BrainXell supports discovery and therapeutic development through a dual-operating model. Learn more at www.brainxell.com.

SOURCE BrainXell, Inc.